MCID: TRM003
MIFTS: 54

Tremor

Categories: Genetic diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Tremor

Summaries for Tremor

MedlinePlus : 42 What is a tremor? A tremor is a rhythmic shaking movement in one or more parts of your body. It is involuntary, meaning that you cannot control it. This shaking happens because of muscle contractions. A tremor is most often in your hands, but it could also affect your arms, head, vocal cords, trunk, and legs. It may come and go, or it may be constant. Tremor can happen on its own or be caused by another disorder. What are the types of tremor? There are several types of tremor, including Essential tremor, sometimes called benign essential tremor. This is the most common type. It usually affects your hands, but it can also affect your head, voice, tongue, legs, and trunk. Parkinsonian tremor, which is a common symptom in people who have Parkinson's disease. It is usually affects one or both hands when they are at rest, but it can affect the chin, lips, face, and legs. Dystonic tremor, which happens in people who have dystonia. Dystonia is a movement disorder in which you have involuntary muscle contractions. The contractions cause you to have twisting and repetitive movements. It can affect any muscle in the body. What causes tremor? Generally, tremor is caused by a problem in the deep parts of the brain that control movements. For most types, the cause is unknown. Some types are inherited and run in families. There can also be other causes, such as Neurologic disorders, including multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury Certain medicines, such as asthma medicines, amphetamines, caffeine, corticosteroids, and medicines used for certain psychiatric and neurological disorders Alcohol use disorder or alcohol withdrawal Mercury poisoning Hyperthyroidism (overactive thyroid) Liver or kidney failure Anxiety or panic Who is at risk for tremor? Anyone can get tremor, but it is most common in middle-aged and older adults. For certain types, having a family history raises your risk of getting it. What are the symptoms of tremor? Symptoms of tremor may include Rhythmic shaking in the hands, arms, head, legs, or torso Shaky voice Difficulty writing or drawing Problems holding and controlling utensils, such as a spoon How is tremor diagnosed? To make a diagnosis, your health care provider Will take your medical history Will do a physical exam, which includes checking Whether the tremor happens when the muscles are at rest or in action The location of the tremor How often you have the tremor and how strong it is Will do a neurological exam, including checking for Problems with balance Problems with speech Increased muscle stiffness May do blood or urine tests to look for the cause May do imaging tests to help figure out if the cause is damage in your brain May do tests which check your abilities to do daily tasks such as handwriting and holding a fork or cup May do an electromyogram. This is a test which measures involuntary muscle activity and how your muscles respond to nerve stimulation What are the treatments for tremor? There is no cure for most forms of tremor, but there are treatments to help manage symptoms. In some cases, the symptoms may be so mild that you do not need treatment. Finding the right treatment depends on getting the right diagnosis of the cause. Tremor caused by another medical condition may get better or go away when you treat that condition. If your tremor is caused by a certain medicine, stopping that medicine usually makes the tremor go away. Treatments for tremor where the cause is not found include Medicines. There are different medicines for the specific types of tremor. Another option is Botox injections, which can treat several different types. Surgery may be used for severe cases that do not get better with medicines. The most common type is deep brain stimulation (DBS). Physical, speech-language, and occupational therapy, which may help to control tremor and deal with the daily challenges caused by the tremor If you find that caffeine and other stimulants trigger your tremors, it may be helpful to cut them from your diet. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Tremor, also known as tremors, is related to fragile x tremor/ataxia syndrome and benign adult familial myoclonic epilepsy. An important gene associated with Tremor is C19orf12 (Chromosome 19 Open Reading Frame 12), and among its related pathways/superpathways are Neuroscience and Parkinsons Disease Pathway. The drugs Acetylcholine and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and subthalamic nucleus, and related phenotypes are behavior/neurological and integument

NINDS : 53 Tremor is an unintentional, rhythmic, muscle movement involving to-and-fro movements of one or more parts of the body. Most tremors occur in the hands, although they can also affect the arms, head, face, voice, torso, and legs. Generally, tremor is caused by a problem in the deep parts of the brain that control movements.  Some forms of tremor are inherited and run in families, while others have no known cause. Sometimes tremor is a symptom of another neurological disorder or a side effect of certain drugs, but the most common form occurs in otherwise healthy people. Excessive alcohol consumption or alcohol withdrawal can kill certain nerve cells, resulting in tremor, especially in the hand. Other causes include an overactive thyroid and the use of certain drugs. Tremor may occur at any age but is most common in middle-aged and older adults. There are several types of tremor, one of the most common of which is essential tremor (sometimes called benign essential tremor). The hands are most often affected but the head, voice, tongue, legs, and trunk may also be involved. Head tremor may be seen as a "yes-yes" or "no-no" motion. Onset is most common after age 40, although symptoms can appear at any age. Parkinsonian tremor is caused by damage to structures within the brain that control movement. The tremor is classically seen as a "pill-rolling" action of the hands but may also affect the chin, face, lips, and legs. Dystonic tremor occurs in individuals of all ages who are affected by dystonia, a movement disorder which causes muscles to be over-active, resulting in abnormal postures or sustained, unwanted movements.

Wikipedia : 74 A tremor is an involuntary, somewhat rhythmic, muscle contraction and relaxation involving oscillations... more...

Related Diseases for Tremor

Diseases in the Tremor family:

Tremor, Hereditary Essential, 1 Tremor, Hereditary Essential, 2
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Tremor, Hereditary Essential, 5 Essential Tremor
Rare Tremor Disorder

Diseases related to Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 836)
# Related Disease Score Top Affiliating Genes
1 fragile x tremor/ataxia syndrome 34.6 LOC108684022 FMR1
2 benign adult familial myoclonic epilepsy 32.4 SAMD12 CNTN2
3 multiple system atrophy 1 32.0 SNCA PRKN MAPT LRRK2 FMR1
4 essential tremor 31.7 TENM4 SNCA PRKN MAPT LRRK2 HTRA2
5 parkinson disease 2, autosomal recessive juvenile 31.6 SNCA PRKN LRRK2 HTRA2
6 machado-joseph disease 31.6 SNCA PRKN ATXN2
7 dystonia 31.5 PRKN LRRK2 FUS DRD3 C19orf12
8 perry syndrome 31.5 SNCA MAPT FUS
9 movement disease 31.4 SNCA PRKN MAPT LRRK2 GBA FUS
10 dementia, lewy body 31.4 SNCA PRKN MAPT LRRK2 GBA FUS
11 neurodegeneration with brain iron accumulation 31.1 SNCA PRKN LRRK2 C19orf12
12 fmr1 disorders 31.0 LOC108684022 FMR1
13 parkinson disease 15, autosomal recessive early-onset 30.9 SNCA PRKN LRRK2 C19orf12
14 aceruloplasminemia 30.7 SNCA MAPT FMR1 C19orf12 ATXN2
15 kufor-rakeb syndrome 30.7 SNCA PRKN LRRK2 C19orf12
16 amyotrophic lateral sclerosis 1 30.4 SNCA PRKN MAPT LRRK2 HTRA2 FUS
17 dysautonomia 30.3 SNCA GBA DNAJC13
18 rem sleep behavior disorder 30.2 SNCA MAPT LRRK2 GBA
19 corticobasal degeneration 30.1 MAPT LRRK2 GBA
20 neuronal intranuclear inclusion disease 30.0 SNCA MAPT
21 parkinson disease, late-onset 29.9 SNCA PRKN MAPT LRRK2 HTRA2 GBA
22 aphasia 29.9 SNCA MAPT LRRK2 FUS
23 motor neuron disease 29.8 SNCA PRKN MAPT FUS
24 olivopontocerebellar atrophy 29.8 SNCA MAPT ATXN2
25 supranuclear palsy, progressive, 1 29.6 SNCA PRKN MAPT LRRK2 FUS ATXN2
26 early-onset parkinson's disease 29.5 SNCA PRKN LRRK2 GBA DRD3
27 frontotemporal dementia 29.5 SNCA MAPT LRRK2 FUS CHCHD2
28 postencephalitic parkinson disease 29.4 SNCA PRKN MAPT LRRK2
29 autosomal dominant cerebellar ataxia 29.4 SNCA PRKN MAPT LRRK2 FUS FMR1
30 restless legs syndrome 29.2 SNCA PRKN MAPT LOC108684022 FMR1 DRD3
31 dementia 29.0 SNCA PRKN MAPT LRRK2 GBA FUS
32 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 28.9 SAMD12 MAPT FUS ATXN2
33 tremor, hereditary essential, 1 12.7
34 primary orthostatic tremor 12.6
35 tremor, hereditary essential, 4 12.6
36 fragile x-associated tremor/ataxia syndrome 12.6
37 tremor, hereditary essential, 5 12.6
38 myopathy, congenital, with tremor 12.6
39 tremor, hereditary essential, 2 12.6
40 tremor, hereditary essential, 3 12.5
41 tremor, nystagmus, and duodenal ulcer 12.3
42 tremor, hereditary essential, and idiopathic normal pressure hydrocephalus 12.3
43 tremor of intention, ataxia, and lipofuscinosis 12.2
44 rare genetic tremor disorder 12.1
45 rare tremor disorder 12.1
46 sensorineural hearing loss-early graying-essential tremor syndrome 12.1
47 epilepsy, familial adult myoclonic, 5 12.1
48 epilepsy, familial adult myoclonic, 1 12.0
49 epilepsy, familial adult myoclonic, 2 12.0
50 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 12.0

Graphical network of the top 20 diseases related to Tremor:



Diseases related to Tremor

Symptoms & Phenotypes for Tremor

MGI Mouse Phenotypes related to Tremor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 ATXN2 CNTN2 DRD3 FMR1 GBA HTRA2
2 integument MP:0010771 9.56 FMR1 GBA HTRA2 LRRK2 MAPT MPZ
3 nervous system MP:0003631 9.44 ATXN2 CNTN2 DRD3 FMR1 GBA HTRA2

Drugs & Therapeutics for Tremor

Drugs for Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 386)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Donepezil Approved Phase 4 120014-06-4 3152
3
Carbidopa Approved Phase 4 28860-95-9 34359
4
Levodopa Approved Phase 4 59-92-7 6047
5
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
6
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
7
Memantine Approved, Investigational Phase 4 19982-08-2 4054
8
Levetiracetam Approved Phase 4 102767-28-2 441341
9
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
10
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
11
Clozapine Approved Phase 4 5786-21-0 2818
12
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
13
Methadone Approved Phase 4 76-99-3 4095
14
Entacapone Approved, Investigational Phase 4 130929-57-6 5281081
15
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
16
Morphine Approved, Investigational Phase 4 57-27-2 5288826
17
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
18
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
19
Racepinephrine Approved Phase 4 329-65-7 838
20
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
21
Amantadine Approved Phase 4 768-94-5 2130
22
Nicotine Approved Phase 4 54-11-5 942 89594
23
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
24
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
25
Polyestradiol phosphate Approved Phase 4 28014-46-2
26
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
27
Cefpirome Approved Phase 4 84957-29-9 5479539
28
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
29
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
30
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
31
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
32
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
33
4-Aminopyridine Approved Phase 4 504-24-5 1727
34
Ziprasidone Approved Phase 4 146939-27-7 60854
35
Histamine Approved, Investigational Phase 4 51-45-6 774
36
Sertraline Approved Phase 4 79617-96-2 68617
37
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
38
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
39
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
40
Acetaminophen Approved Phase 4 103-90-2 1983
41
Prilocaine Approved Phase 4 721-50-6 4906
42
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
43
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
44
Remifentanil Approved Phase 4 132875-61-7 60815
45
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
46
Iodine Approved, Investigational Phase 4 7553-56-2 807
47
tannic acid Approved Phase 4 1401-55-4
48
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
49
Zinc Approved, Investigational Phase 4 7440-66-6 32051
50
Metformin Approved Phase 4 657-24-9 4091 14219

Interventional clinical trials:

(show top 50) (show all 622)
# Name Status NCT ID Phase Drugs
1 A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control and Pari Nebulization for the Treatment of Adults With Moderate Asthma Unknown status NCT00385359 Phase 4 Albuterol
2 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Unknown status NCT03098368 Phase 4 Rotigotine;Placebo
3 A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
4 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
5 The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
6 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
7 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
8 A Multi-site, Double-blind, Randomized, Placebo-controlled, Crossover Study of Pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
9 A Pilot Clinical Trial of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
10 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
11 A 17 Week, Investigator-initiated, Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Trial of Pregabalin in Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
12 An Open Label Evaluation of MIDI to Quantify Performance Change in Subjects With Musician's Dystonia After Treatment With Botulinum Toxin Type B (Myobloc ®). Completed NCT00208091 Phase 4 Botulinum toxin, type B
13 Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Oculopalatal Tremor: a Controled Open-label Study Completed NCT02466191 Phase 4 Memantine;Gabapentin
14 A Multicentre, Randomised, Open Label, Comparative Phase 4 Trial to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism in a General Neurologist Setting. Completed NCT00382967 Phase 4
15 A Comparison Study of the Efficacy and Tolerability Between Depakote ER and Depakote in the Acute Treatment of Mania and Mixed Mania Completed NCT00334347 Phase 4 Depakote ER;Depakote DR
16 A 16 WEEK, INVESTIGATOR-INITIATED, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NAMENDA® (MEMANTINE HCL) FOR NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE Completed NCT00646204 Phase 4 Memantine;placebo
17 Aripiprazole for Clozapine Associated Medical Morbidity Completed NCT00345033 Phase 4 Aripiprazole;Placebo
18 A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms Completed NCT00297778 Phase 4 Pramipexole
19 A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off Completed NCT00219284 Phase 4 Carbidopa/levodopa/entacapone
20 Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
21 A Pilot Study of Corticosteroid-Free, Calcineurin-Sparing Immunosuppression Protocol for HLA-Identical Living Donor Renal Transplant Recipient Completed NCT00352092 Phase 4 calcineurin inhibitor;sirolimus;mycophenolate mofetil
22 The Effects of Levetiracetam on Alcohol Dependent Subjects Completed NCT00325182 Phase 4 Levetiracetam
23 Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators Completed NCT02256319 Phase 4 Dexmedetomidine;Propofol
24 A Multicenter, Open-Label, Two-Arm Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management Completed NCT03103919 Phase 4 Rotigotine
25 Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's Disease Completed NCT00908076 Phase 4 LUBIPROSTONE
26 Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children Completed NCT00790075 Phase 4 risperidone
27 Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain in Patient Undergoing Diagnostic Gynacological Laproscopy. A Randomized Controlled Trial Completed NCT03241602 Phase 4 Intraperitoneal lidocaine
28 The Impact of the Prophylactic or Therapeutic Application of Bryophyllum on Preterm Delivery - a Prospective Study Completed NCT00163579 Phase 4 Bryophyllum
29 RNS® System Long-term Treatment (LTT) Clinical Investigation Completed NCT00572195 Phase 4
30 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
31 A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis Completed NCT00337350 Phase 4 rosiglitazone;placebo
32 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
33 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. Completed NCT00640159 Phase 4 Zelapar
34 A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
35 The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial Completed NCT02914652 Phase 4 Salbutamol;Norflouran (Placebo Evohaler(R) )
36 A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
37 Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus. Completed NCT01714011 Phase 4 Ziprasidone;Aripiprazole
38 A Comparison of Bupropion SR and Placebo for Smoking Cessation Completed NCT00176449 Phase 4 Bupropion SR;Placebo Oral Tablet
39 Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Mild to Moderately Severe Bronchiolitis - A Double Blind Randomized Controlled Trial. Completed NCT01276821 Phase 4 L-Epinephrine and Normal Saline (0.9%);L-Epinephrine and Hypertonic Saline (3%)
40 QUALITY OF RECOVERY AFTER INTRAOPERATIVE MORPHINE OR METHADONE IN PATIENTS UNDERGOING LAPAROSCOPIC CHOLECYSTECTOMY Completed NCT03045133 Phase 4 Methadone;Morphine
41 A Study of Sertraline to Prevent PTSD Completed NCT00182078 Phase 4 Placebo;Sertraline
42 Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients Recruiting NCT03713645 Phase 4 Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
43 A Placebo-controlled, Double-blind, Randomized, Cross Over Pilot Study of the Efficacy and Tolerability of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor Recruiting NCT03136341 Phase 4 Abobotulinum toxin A
44 Clinical Evaluation of Switching to Lithiofor® (Lithium Sulphate Slow -Release, Li-SR Tablets) From Carbolithium® (Lithium Carbonate Immediate-Release, Li-IR, Capsules) in Bipolar Patients, Poorly Tolerant to Lithium Immediate-release Treatment. Recruiting NCT03210480 Phase 4 Lithium sulphate prolonged-release 660 mg;Lithium carbonate immediate-release 150 mg and 300 mg
45 Comparison of Analgesic Effects of Gabapentin and Paracetamol in Patients With Hand Injury Recruiting NCT04068506 Phase 4 Gabapentin 600 mg Tab
46 Lidocaine Versus Ketorolac for the Management of Renal Colic Recruiting NCT03137498 Phase 4 Lidocaine;Ketorolac
47 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
48 Effects of Anesthesia Drugs on Neuronal Activity in the Basal Ganglia and Thalamus During Deep Brain Stimulation Electrode Implantation Surgery Recruiting NCT03283150 Phase 4 Remifentanil;Propofol;Dexmedetomidine
49 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
50 Atlas Predicted DBS Settings in Essential Tremor Active, not recruiting NCT02678429 Phase 4

Search NIH Clinical Center for Tremor

Genetic Tests for Tremor

Genetic tests related to Tremor:

# Genetic test Affiliating Genes
1 Tremor 29

Anatomical Context for Tremor

MalaCards organs/tissues related to Tremor:

40
Brain, Testes, Subthalamic Nucleus, Thalamus, Liver, Thyroid, Cortex

Publications for Tremor

Articles related to Tremor:

(show top 50) (show all 21537)
# Title Authors PMID Year
1
Deep Brain Stimulation of the Caudal Zona Incerta and Motor Thalamus for Postischemic Dystonic Tremor of the Left Upper Limb: Case Report and Review of the Literature. 42 61
30738935 2019
2
Deep Brain Stimulation for Treatment of Tremor. 42 61
30898267 2019
3
Unilateral Thalamic Deep Brain Stimulation for Voice Tremor. 42 61
30625492 2018
4
Diagnosis and Differential Diagnosis of Parkinson Disease. 61
31733693 2020
5
Does This Patient Have Parkinson Disease or Essential Tremor? 61
31733699 2020
6
Neuroimaging of Deep Brain Stimulation. 61
31761059 2020
7
Improved detection of Parkinsonian resting tremor with feature engineering and Kalman filtering. 61
31744673 2020
8
Early-onset Parkinsonian behaviors in female Pink1-/- rats. 61
31542395 2020
9
Differentiating Parkinson Disease Subtypes Using Clinical Balance Measures. 61
31834219 2020
10
Parkinson disease. 61
31631455 2020
11
Advanced technologies for detecting tremor in Parkinson's disease. 61
31806418 2020
12
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. 61
31666199 2020
13
Artificial intelligence and robotic surgery: current perspective and future directions. 61
31724999 2020
14
Efficacy of oral administration of licorice as an adjunct therapy on improving the symptoms of patients with Parkinson's disease, A randomized double blinded clinical trial. 61
31574343 2020
15
Genetic and phenotypic features of patients with childhood ataxias diagnosed by next-generation sequencing gene panel. 61
31493945 2020
16
In Vitro Synthesis and RNA Structure Probing of CUG Triplet Repeat RNA. 61
31586349 2020
17
UPLC-HDMS-based on serum metabolomics reveals the toxicity of arecae semen. 61
31553926 2020
18
Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? 61
31669925 2020
19
Brain 123I-FP-CIT SPECT of a Holmes Tremor Due to Midbrain Pilocytic Astrocytoma. 61
31306206 2020
20
Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. 61
31753915 2020
21
Effects of ventral intermediate nucleus deep brain stimulation across multiple effectors in essential tremor. 61
31794958 2020
22
Cerebellar repetitive transcranial magnetic stimulation (rTMS) for essential tremor: A double-blind, sham-controlled, crossover, add-on clinical trial. 61
31624048 2020
23
Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions. 61
31837424 2019
24
Alzheimer's Disease and Parkinson's Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and Environmental Chemicals. 61
31829802 2019
25
Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson's disease mice model. 61
31820278 2019
26
Predicting high-intensity focused ultrasound thalamotomy lesions using 2D magnetic resonance thermometry and 3D Gaussian modeling. 61
31621080 2019
27
[Diagnostic value of tremor analysis in identifying the early Parkinson's syndrome]. 61
31848511 2019
28
Visuomotor characteristics and differences between the tremor-dominant and akinetic-rigid type of Parkinson's disease. 61
31847603 2019
29
Secondary Parkinson disease caused by breast cancer during pregnancy: A case report. 61
31832408 2019
30
Modulation of Nigrofugal and Pallidofugal Pathways in Deep Brain Stimulation for Parkinson Disease. 61
31832650 2019
31
Bimanual Gesture Imitation Links to Cognition and Olfaction. 61
31441513 2019
32
Differential expression of nicotine withdrawal as a function of developmental age in the rat. 61
31669000 2019
33
Clinical Presentation of Ataxia-Telangiectasia. 61
31823618 2019
34
Bag of Samplings for computer-assisted Parkinson's disease diagnosis based on Recurrent Neural Networks. 61
31605890 2019
35
Prevalence of self-reported movement dysfunction among young adults with a history of ecstasy and methamphetamine use. 61
31600615 2019
36
Tremor Assessment during Virtual Reality Brain Tumor Resection. 61
31822389 2019
37
Mapping holmes tremor circuit using the human brain connectome. 61
31614012 2019
38
Focal localized enhanced physiological tremor after physical insult. 61
31214870 2019
39
Current Opinions and Consensus for Studying Tremor in Animal Models. 61
31124049 2019
40
Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort. 61
31837152 2019
41
Adaptation effects of medial forebrain bundle micro-electrical stimulation. 61
30916601 2019
42
Single-Agent Bupropion Exposures: Clinical Characteristics and an Atypical Cause of Serotonin Toxicity. 61
31823333 2019
43
Safety and efficacy of magnetic resonance imaging-guided focused ultrasound neurosurgery for Parkinson's disease: a systematic review. 61
31814058 2019
44
Reliability of Intraoperative Testing During Deep Brain Stimulation Surgery. 61
31823438 2019
45
Repeated Intravenous Amantadine Infusions in Advanced Parkinsonism: Experience of a Large Movement Disorder Center. 61
31814345 2019
46
Molecular Survey and Phylogenetic Analysis of Atypical Porcine Pestivirus (APPV) Identified in Swine and Wild Boar from Northern Italy. 61
31835549 2019
47
Severe illicit gamma-hydroxybutyric acid withdrawal in a pregnant woman: what to do? 61
31796453 2019
48
d-Glycerate kinase deficiency in a neuropediatric patient. 61
31837836 2019
49
Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease. 61
31839530 2019
50
Choline transporter-like 1 deficiency causes a new type of childhood-onset neurodegeneration. 61
31855247 2019

Variations for Tremor

ClinVar genetic disease variations for Tremor:

6 (show all 12) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 LOC101927919 , NUS1 , SLC35F1 NC_000006.11:g.(117961791_117961792)_(118280043_118280044)deldeletion Pathogenic 180225 6:117961791-118280044 6:117640628-117958881
2 LOC101927919 , NUS1 NC_000006.11:g.(117971549_117971550)_(118218719_118218720)deldeletion Pathogenic 180226 6:117971549-118218720 6:117650386-117897557
3 covers 24 genes, none of which curated to show dosage sensitivity NC_000006.11:g.(116681080_116735056)_(119687719_119775014)deldeletion Pathogenic 180227 6:116681080-119775014
4 TMEM67 NM_001142301.1(TMEM67):c.1600T>C (p.Cys534Arg)SNV Pathogenic/Likely pathogenic 1383 rs201893408 8:94808198-94808198 8:93795970-93795970
5 C19orf12 NM_001256047.1(C19orf12):c.172G>A (p.Gly58Arg)SNV Pathogenic/Likely pathogenic 31157 rs515726205 19:30193873-30193873 19:29702966-29702966
6 TMEM67 NM_001142301.1(TMEM67):c.1078C>T (p.Arg360Cys)SNV Pathogenic/Likely pathogenic 217725 rs752362727 8:94798483-94798483 8:93786255-93786255
7 GBA NM_000157.4(GBA):c.1093G>A (p.Glu365Lys)SNV risk factor 199044 rs2230288 1:155206167-155206167 1:155236376-155236376
8 MPZ NM_000530.8(MPZ):c.699T>G (p.Ser233Arg)SNV Likely pathogenic 374017 rs1057518839 1:161275714-161275714 1:161305924-161305924
9 C19orf12 NM_001256047.1(C19orf12):c.391A>G (p.Lys131Glu)SNV Conflicting interpretations of pathogenicity 31158 rs146170087 19:30193654-30193654 19:29702747-29702747
10 GLI2 NM_005270.4(GLI2):c.2644A>T (p.Thr882Ser)SNV Uncertain significance 523482 rs1332140763 2:121746134-121746134 2:120988558-120988558
11 ADGRV1 NM_032119.4(ADGRV1):c.5188A>T (p.Ile1730Phe)SNV Uncertain significance 523543 rs1554079046 5:89971137-89971137 5:90675320-90675320
12 CACNA1H NM_021098.3(CACNA1H):c.6884C>T (p.Ser2295Phe)SNV Uncertain significance 523531 rs772718469 16:1270816-1270816 16:1220816-1220816

Copy number variations for Tremor from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 247217 9 129375646 129461836 Deletion FAM129B Tremor
2 247222 9 129375646 129461836 Deletion STXBP1 Tremor

Expression for Tremor

Search GEO for disease gene expression data for Tremor.

Pathways for Tremor

Pathways related to Tremor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 SNCA PRKN MAPT LRRK2 FMR1 CNTN2
2 10.95 SNCA PRKN LRRK2 HTRA2 ATXN2

GO Terms for Tremor

Cellular components related to Tremor according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 10.02 SNCA PRKN MAPT LRRK2 HTRA2 CHCHD2
2 cell projection GO:0042995 9.93 TMEM67 TENM4 MAPT LRRK2 FMR1 DRD3
3 axon GO:0030424 9.72 SNCA MAPT LRRK2 FMR1 CNTN2
4 postsynapse GO:0098794 9.67 SNCA LRRK2 FMR1
5 synaptic vesicle membrane GO:0030672 9.61 SNCA LRRK2 DRD3
6 mitochondrial intermembrane space GO:0005758 9.54 SNCA HTRA2 CHCHD2
7 inclusion body GO:0016234 9.51 SNCA LRRK2
8 growth cone GO:0030426 9.46 SNCA MAPT LRRK2 FMR1
9 polysome GO:0005844 9.43 FUS FMR1 ATXN2
10 neuron projection GO:0043005 9.43 TENM4 PRKN MAPT LRRK2 FMR1 CNTN2
11 glial cell projection GO:0097386 9.4 MAPT FMR1
12 neuronal cell body GO:0043025 9.1 SNCA MAPT LRRK2 FUS FMR1 CNTN2

Biological processes related to Tremor according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 response to oxidative stress GO:0006979 9.83 PRKN LRRK2 C19orf12
2 cellular response to oxidative stress GO:0034599 9.78 SNCA LRRK2 HTRA2
3 negative regulation of protein phosphorylation GO:0001933 9.77 SNCA PRKN LRRK2
4 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.76 PRKN LRRK2 GBA
5 regulation of autophagy GO:0010506 9.75 PRKN MAPT LRRK2
6 learning GO:0007612 9.73 PRKN DRD3 CNTN2
7 adult locomotory behavior GO:0008344 9.69 SNCA PRKN HTRA2
8 regulation of neuronal synaptic plasticity GO:0048168 9.65 SNCA CNTN2
9 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.65 PRKN LRRK2
10 autophagy GO:0006914 9.65 PRKN LRRK2 GBA DRD3 C19orf12
11 regulation of neuron death GO:1901214 9.64 SNCA LRRK2
12 behavioral response to cocaine GO:0048148 9.64 SNCA DRD3
13 cellular protein catabolic process GO:0044257 9.63 PRKN HTRA2
14 positive regulation of proteasomal protein catabolic process GO:1901800 9.63 PRKN FMR1
15 stress granule assembly GO:0034063 9.62 MAPT ATXN2
16 cellular response to dopamine GO:1903351 9.62 PRKN LRRK2
17 negative regulation of voltage-gated calcium channel activity GO:1901386 9.61 FMR1 DRD3
18 regulation of dopamine secretion GO:0014059 9.61 SNCA PRKN DRD3
19 supramolecular fiber organization GO:0097435 9.6 SNCA MAPT
20 regulation of neurotransmitter secretion GO:0046928 9.58 SNCA PRKN FMR1
21 cellular response to manganese ion GO:0071287 9.57 PRKN LRRK2
22 regulation of mitochondrial fission GO:0090140 9.55 MAPT LRRK2
23 intracellular distribution of mitochondria GO:0048312 9.54 MAPT LRRK2
24 synaptic transmission, dopaminergic GO:0001963 9.54 SNCA PRKN DRD3
25 protein localization to mitochondrion GO:0070585 9.52 PRKN LRRK2
26 dopamine metabolic process GO:0042417 9.5 SNCA PRKN DRD3
27 dopamine uptake involved in synaptic transmission GO:0051583 9.49 SNCA PRKN
28 positive regulation of dopamine receptor signaling pathway GO:0060161 9.48 LRRK2 DRD3
29 regulation of synaptic vesicle transport GO:1902803 9.46 PRKN LRRK2
30 mitochondrion organization GO:0007005 9.35 PRKN LRRK2 HTRA2 GBA CHCHD2
31 regulation of locomotion GO:0040012 9.33 SNCA LRRK2 DRD3
32 negative regulation of neuron death GO:1901215 9.02 SNCA PRKN LRRK2 HTRA2 GBA

Molecular functions related to Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.46 SNCA MAPT LRRK2 FMR1
2 dynein complex binding GO:0070840 9.32 SNCA FMR1
3 identical protein binding GO:0042802 9.28 TENM4 SNCA PRKN MAPT LRRK2 HTRA2
4 phospholipase binding GO:0043274 9.26 SNCA PRKN
5 tubulin binding GO:0015631 9.13 PRKN MAPT LRRK2

Sources for Tremor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....